A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.
Also called NCT01242228
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 106 participants
- Sponsor
- Registry
-
NCT01242228
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01242228. Allocation not applicable; no masking; primary purpose treatment. Start 2010-10-21 (actual); primary completion 2012-06-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- ipragliflozin
- Intervention (Drug)
- DPP-4 inhibitor
- Lead sponsor
- Astellas Pharma Inc
Record details
- Record id
cardio:ct-nct01242228- Content hash
2885dc7aa3d302cb58015982c6ff0b0cdb3ed75005a2d44e25f9da6a4d5658f5